S227928
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 132 patients (estimated)
- Sponsors
- Servier Bio-Innovation LLC
- Tags
- Antibody Drug Conjugate (ADC), Myeloid Cell Leukemia-1 (MCL-1) Inhibitor, CD74
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 2114
- NCT Identifier
- NCT06563804
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.